January 10, 2018 / 1:44 PM / 5 months ago

BRIEF-Moleculin Expands Leukemia Development Portfolio With Immuno-Stimulating Stat3 Inhibitor

Jan 10 (Reuters) - Moleculin Biotech Inc:

* MOLECULIN EXPANDS LEUKEMIA DEVELOPMENT PORTFOLIO WITH IMMUNO-STIMULATING STAT3 INHIBITOR

* MOLECULIN BIOTECH INC - EXPANDED COMPANY'S DEVELOPMENT PIPELINE FOR TREATMENT OF ACUTE MYELOID LEUKEMIA WITH AN IMMUNO-STIMULATING STAT3 INHIBITOR Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below